Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
New competition for CTSO?
HGEN moved up big on news of $72 million PP for developing lenzilumab to treat cytokine storm. Current focus: coronavirus, of course.
The pharmas always seem to draw the $$.
See Post No. 32965. Way before you started to follow LWLG MB.
I also am doubting any $0.30 cent bargain for LWLG stock will be coming my way. However, I would not be surprised to see a PPS pullback this month in particular. When market averages are hitting new highs October has historically seen some big drops.
But not for all stocks, of course. You must be pleased, and relieved, with the gain in SG MO since May. I am expecting that LWLG will eventually have a nice breakout to the upside. When, I don't know.
Well, I would not put it that way, because I saw no evidence of resolution in the legal dustup between Messrs Bovi and Senger (descriptive adjectives aside). Many legal cases are settled privately out of court. So there may not be a public record.
LinkedIn recommendations usually come from satisfactory business and personal relations. LinkedIn shows that Mr. Bovi currently has a number of them. The one by Dr. Laser struck me as informative. Maybe you weren't impressed -- that's your call.
If LWLG leadership finds something significant about Mr. Bovi's actions in the past they will, I am confident, resolve it in a sensible business way.
The relationship between LWLG Securities Counsel David M. Bovi and noted oil business leader Charles Laser, who along with others recommended Mr. Bovi on LinkedIn, is more current, more relevant, and indicates to me the qualities that commended Mr. Bovi to the LWLG BOD.
David Bovi
Attorney at David M. Bovi, P.A.
West Palm Beach, Florida Area
Law Practice
Current
David M. Bovi, P.A.
Education
Georgetown University Law Center
Recommendations 11 people have recommended David
https://www.linkedin.com/in/david-bovi-34b630b
Charles Laser
Charles Laser is a true oil wildcatter—an independent oil and gas explorer—who's been working in the oil industry for over 40 years. President of Laser Exploration, Inc., an oil and gas exploration company based in Florida, Laser graduated from West Branch High School in West Branch, Michigan in 1952. He attended Michigan Technological University for two years and then spent another two years in the United States Army when he was honorably discharged in 1958.
Laser formed his own company, Laser Exploration, Inc. in 1974 in Deerfield Beach, Florida and managed it while working for GeoSpectra. His company conducts oil and gas exploration across the United States, as well as buys and sells land leases. Laser's company has operations in Wyoming and Michigan, where the company owns several wells. Laser's oil and gas explorations have taken him to Illinois, Indiana, Texas, Colorado, Montana and more recently, Nevada. In 2006, Laser was named as a member of the Advisory Board for the Victory Capital Holdings Corporation, a publicly-traded company dedicated to energy technologies, based out of Nevada.
During his career, Laser has acquired more than 400,000 acres of gas and oil leases across the United States. He's been involved with four discoveries and has consulted with oil companies across the globe. Laser has worked with companies such as Exxon, Chevron, AMOCO, ARCO, Texaco, Mobil and DeBeers. He was also a strategic negotiator in a multi-million [dollar] oil deal with a Canadian company involving 15 oil wells.
Laser's been noted and listed in the following publications: "Who's Who in America," "Who's, Who in Finance and Industry," "Who's Who in Science," "Who's Who in the South," and "Who's Who in the World."
http://www.usdreams.com/Laser.html
Some people may want to spend their lives focused on sunspots. Much better IMO to support Lightwave's efforts which may include harnessing solar energy in innovative, sustainable, and profitable ways. Enrich the world and enjoy the benefit of investing in its multifaceted potential.
It would be nice if wonderful pps gains happened soon.
I'll be glad if $2.74 is reached within a year to edge above the Target Price of $2.71 by See Through Equity in the "technology productization" year of 2014.
Youtube:
Theroc,
Looking at estimates for earnings within four years, you project $1 billion sales and $500 million gross earnings (your numbers, my terms).
From these assumptions, I don't see how you arrive at an estimated EPS of $100. It seems high to me (also very tantalizing).
How many shares outstanding are you assuming in your calculations? Are you estimating on an annual basis or some other period of time?
TIA for your help.
Info
Thanks, James. Important indeed! This kind of post should encourage many.
Rambos, I'm sorry that you are departing because you feel you are unwelcome here. That's not my sentiment.
You drew my attention to the stock years ago. I appreciated your contributions in tech analysis. Like many, I expected rapid results.
A while back I blundered and the offended party on this MB gave me a direct smack-down. I shut up for a while and learned (I hope) to be more wary of how others advance/protect their interests. And how to tell the LWLG story.
Through the years I increased my holdings way beyond prudent risk boundaries, but thought the Lightwave approach was scientifically well-founded. Meanwhile your wide-ranging pursuits apparently have brought you greater profits than my "stick with the goo" tactic.
Whatever happens, I don't want you to check out without my thanks. I wish you good trading.
Breaking news! World cobalt supply is going into deficit according to the CEO of Fortune Minerals, a developing supplier of cobalt that is a vital component sf the cathode and energy flow in lithium-ion batteries. Gigafactories now under construction face a serious constraint.
https://www.midasletter.com/podcast/fortune-minerals-ltd-ceo-robin-goad-cobalt-supply-tesla-inc-volkswagen/
But wait! If the newly developed low-cost, all-solid-state battery that is both non-combustible and fast-charging proves viable, battery producers could make a fast pivot. The combination of glass electrodes and low-cost sodium instead of lithium has the additional advantages of a long life cycle and at least three times the energy density of current lithium-ion batteries. A serious challenge indeed!
https://blogs.scientificamerican.com/plugged-in/engineers-introduce-a-new-fast-charging-noncombustible-battery/
Thank you for the update. Within a week we may have a judgment, . . . or not??
Is this the last court case? If so, shares may move at last.
Perhaps of interest: Dr. James Andrews of sports medicine fame got mention in the "Football in America" article in Sports Illustrated, Nov. 21 last year (double issue) on pages 50-51. No mention of SVFC among his orthopedic tools of the trade. Sigh! He's still the most sought after man for athletic injuries and is listed among the 10 richest docs in the world at $100 million last year.
No wonder he does not bother with Dr. Victor. ReGen Medical still uses SVF cells as a part of its practice, and IntelliCell is still mentioned on its web site in a 2016 article and the web site with a 2017 copyright date. So its still a viable technology. All rather murky business to me.
Yahoo News now featuring this article: "How baseball players are trying stem cells to avoid Tommy John"
More great stem cell use than ever. And SVFC . . . I'm still holding and waiting.
Press Release
Amarillo Biosciences, Inc. Receives Approval of Patent Claims - Treatment of Thrombocytopenia Using Orally Administered Interferon
Published: Oct 6, 2016 9:32 a.m. ET
Oct 06, 2016 (ACCESSWIRE via COMTEX) -- AMARILLO, TX / ACCESSWIRE / October 6, 2016 / Amarillo Biosciences, Inc. (ABI) AMAR, +15.20% today announced that eight claims of its latest patent application, which apply the use of low-dose oral interferon to the reversal of Thrombocytopenia, have been allowed by the U.S. Patent & Trademark Office. The patent is expected to issue before year end, 2016. ABI has full rights to exploit this patent in the U.S., Africa, India, Thailand, Malaysia, Australia, New Zealand, Indonesia, the Philippines, and certain other smaller markets.
"Approval of this patent signifies a very important milestone for ABI and for medicine," said Dr. Stephen T. Chen, Chairman and CEO of the Company. "Low dose oral interferon has been proven to be extremely safe for human therapies. Furthermore, our low-dose oral interferon has shown very positive results in various clinical trials. Issuance of this patent will expedite the development and commercialization of the new treatment and usher the product into global markets."
Thrombocytopenia is a blood system disorder in which there is a reduction in the thrombocyte (platelet) count caused by suppression of bone marrow, the blood-producing organs. The use of high-dose injectable interferon, chemotherapies, nonsteroidal anti-inflammatory drugs (NSAIDs), penicillin, antibiotics and other strong, harsh medicines used in the treatment of diseases and chronic conditions, cause such an effect on the bone marrow and platelets. Platelets play the key role in the formation of blood clots which prevent and stop hemorrhage (uncontrolled bleeding) from a ruptured or injured blood vessel. Thrombocytopenia increases the risk of spontaneous bleeding, which could become fatal if it occurs in the head (intracranial areas) or from the lining of the stomach or somewhere else in the gastrointestinal system.
Although not yet approved by U.S. FDA, ABI believes that low-dose oral interferon will prove to be a safe and affordable treatment for people with severe or life-threatening thrombocytopenia. Current treatments are effective but expensive and come with serious side effects and surgical risks. Such treatments include Immunoglobulin therapy (IVIG) given through a vein, plasma exchange (plasmapheresis), platelet transfusions, and corticosteroid medicine.
The scientific proof for this patent came out of a clinical trial conducted in Taiwan between 2009 and 2012. This trial was designed to use low dose oral interferon to help prevent viral recurrence in hepatitis C patients who have received the combination conventional therapy - high-dose injectable interferon-a and ribavirin. As a result of receiving this therapy, numerous patients suffered thrombocytopenia. Surprisingly, platelet counts of one treatment group, in which patients received 500IU of low dose oral interferon daily, quickly recovered back to the normal range within 4 weeks and the patients experienced almost no adverse side effects. The results were highly statistically significant (p = 0.003).
"ABI is very confident that low dose oral interferon will prove to be far superior to those thrombocytopenia drugs currently on the market. We are actively seeking partnerships in future development opportunities," added Dr. Chen.
About Amarillo Biosciences, Inc. (www.amarbio.com)
Amarillo Biosciences, Inc. (ABI) is a Texas corporation formed in 1984 that engaged in developing biologics for the treatment of human and animal diseases. Such human disease research includes influenza, hepatitis C, Chronic Cough in COPD, thrombocytopenia caused by other diseases and as a side effect of treatment of other diseases, and other disease indications using natural human interferon alpha that is administered in a proprietary low dose oral form. ABI has conducted more than 100 pre-clinical (animal) and human studies on the safety and efficacy of low-dose orally administered interferon. The Company is aggressively seeking partners with which to build relationships for new areas of discovery and expansion.
The Company has reorganized and restructured into three business units: the Medical, Pharmaceutical, and Consumer Product Divisions. These divisions will serve to create multiple revenue streams through the implementation of programs (including but not limited to in-licensing) of novel medical and health care products and processes. The overall operating strategy is for ABI to create a world-wide network of strategic alliances capitalizing on advanced and emerging technologies in order to engineer a diversified enterprise having a major impact on every aspect of the healthcare and life sciences industries. In addition, assemble an exhaustive pipeline of technologically-advanced, cutting edge products and services with which to compete in the American and Asian markets.
Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates (including geographic placement of products) and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.
Investor Relations: Bernard Cohen
Amarillo Biosciences, Inc. Tel: 806-376-1741 Extension 16
Fax: 806-376-9301
E-mail: bcohen@amarbio.com
SOURCE: Amarillo Biosciences, Inc.
http://www.accesswire.com/img.ashx?id=446587
Copyright 2016 ACCESSWIRE
Noticed this was not posted here. A bit dated but potentially significant. The principal investors in AMAR are holding and still buying, so we will see what develops in future months. Time to watch and wait; no need to hyperventilate and pump.
Rickface addressed the tech part. The ECOC Conference Presentation, September 19, 2016 provides bigger industry context (Link at the LWLG website under News). Some items that caught my eye.
ECOC slide 12 shows that using VCSEL laser driven data through older multi-mode fiber faces a barrier at distances beyond 200 meters. Single mode fiber is the future for data centers.
Slide 13 shows that 10G to 100G speeds have been "sweet spots" in data centers since 2010. Even 25GG devices are still in development, but "400Gbps represents the next 'sweet spot' for network designers."
Slide 14 emphasizes that power requirements are forcing new form factors in transceiver design, according to the Ethernet Alliance.
Slide 15 shows the current dominance of 40G X 10 transceivers in line cards for 400G data rates. Integrated photonics will improve this.
Slide 33 compares crystalline materials with electro-optical (EO) polymers. Polymers offer many advantages for future needs.
Slide 35 shows how Polymer slot modulators (not now available) will integrate into a silicon platform and enable 100Tbps data rates.
Slide 36 asserts that LWLG has demonstrated a slot modulator on a Silicon platform.
Slides 38, 39 show various Polymer Photonics (PP) advantages.
Slide 40 compares tech values; shows unique PP advantages beyond current 100G systems available now from some suppliers.
Slide 41 shows tech specs of five EO Polymer state-of-the-art items.
Remaining slides show LWLG vehicles for PPIC growth, profits.
Hi Super,
This isn't the big news such as a partnership or contract for completed and tested product would be.
But I didn't expect that, so I am not disappointed. I am encouraged that the staff made good progress toward goals that will enable "big news" in the future. Waiting is hard, but realistic.
Here's the important point for me: "Our development plan didn't anticipate attaining a 10 Gbps data rate until the first quarter of 2017, but due to exceptional engineering work, we were able to exceed this goal, and demonstrate true amplitude (intensity) modulation in a Mach-Zehnder modulator structure incorporating our polymer waveguides.
Markus, I think this may be confusing for those who lack the historical context of longer-term investors. Here's what we know:
"Tom Zelibor, Chairman and CEO of Lightwave Logic stated, "Over the last two years we have been extending the capabilities of our P2IC™
design platform. We began with groundbreaking discoveries in polymer synthesis that are currently being implemented in our new device designs. We intend to boost performance and drive down cost similar towhat was seen in the computer integrated circuit business over the last 60 years.
"During the next several months we will unveil our first ridge waveguide modulator to address the requirements of theOC48 (2.5 Gbps) and OC192 (10 Gbps) carrier market. Given the amount of industry interest we have previously received, this initial effort is designed to prove that our P2IC™ platform can meet commercial requirements. However, theultimate goal remains to demonstrate that our technology is scalable to 200 Gbps and beyond."
Source: Lightwave Logic Designing Cost Effective HighSpeed Silicon Photonics Solutions Enabled By Its P(2)IC™ Polymer Photonics Integrated Circuit) PlatformHigh-Density Photonic Circuitry On Silicon, Enabled By Thin Film Polymer Coatings Increases Data Rates and Reduces Cost. LONGMONT, Colo., July 12, 2016/PRNewswire/
The stated goal for 2016 was 2.5 GBPS and for 1Q17 it was 10 Gbps as posters here generally understood it. So the data rates approaching 10 Gbps exceeded this years goal of a 2.5 Gbps device.
We expect much more development beyond 10 Gbps toward commercial goals as Dr. Lebby presented it in August (Post #20320).
The author is a member of Anavex's Scientific Advisory Board.
The focus is looking at approvals of recent Antiepileptic Drugs (AEDs) in historical context. Numerous aspects of the topic have been discussed or questioned by recent posts here. They include approvals, approvals to monotherapy, initial monotherapy, placebo-controlled trials, off-label drug use, international standards making US monotherapy approval difficult, problems with trreatment-resistant patients, ethics and practical issues with placebo-control, pseudoplacebo trials, withdrawal to monotherapy, methods and results of several recent trials, etc.
This sampling is incomplete. The paper is worth a look for those concerned with the Anavex AED effort, IMO.
Today my fidelity account showed 0.00001 price for SVFC. That's a drop of 90%.
Any other brokerage houses that reflect this price drop? What's up (or down)?
I picked up 2,000 today on the OTC. Been waiting a while for price pullback, which IMO is due to various uncertainties. Glad to be long here.
If it happened we would find out how many ILNS shares outstanding.
Recent article about stromal vascular fraction research -- $USRM stock worth 2 cents, but not because of Dr. Vic!
Published By Kristin Comella, USRM Chief Science Officer
Effects of the intramyocardial implantation of stromal vascular fraction in patients with chronic ischemic cardiomyopathy
CSO Kristin Comella Publishes Paper on the Implantation of Stromal Vascular Fraction in Patients with Cardiomyopathy
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4890248/pdf/12967_2016_Article_918.pdf
https://finance.yahoo.com/news/cso-kristin-comella-publishes-paper-130000318.html
Unsure if our big lead is fast vanishing, but am sure competition is working to close the gap. A recent example:
https://www.sciencedaily.com/releases/2016/08/160815134945.htm
An article claiming a "New world record for fullerene-free polymer solar cells" was published four months ago by researchers in China. Not sure if this was posted earlier. It resembles the article you linked to on organic based photovoltaic technology.
https://www.sciencedaily.com/releases/2016/04/160419103847.htm?trendmd-shared=0
Getting invited to the ECOC meant making a credible case.
Tom Zelibor, Chairman and CEO of Lightwave Logic commented, "We are honored that the ECOC board accepted our written technical paper submission and have invited us to introduce our advanced organic electro-optic polymer technology to this important audience of industry decision makers."
Is the "written technical paper" somewhere in the "white paper" arena? Not fully public, but it helped to convince the ECOC program gate-keepers. Congrats to Dr. Lebby and the LWLG team.
AVXL Short Interest released today by NASDAQ
Settlement Date 7/29 ** Short Interest 4,599,225 ** Avg Daily Share Volume 2,577,268 ** Days To Cover 1.784535
Read more: http://www.nasdaq.com/symbol/avxl/short-interest#ixzz4GtnBYP1S
ADXS short interest today from NASDAQ
Settlement Date 7/29 Short Interest 8,182,438 Avg Daily Share Volume 467,181 Days To Cover 17.514492
Read more: http://www.nasdaq.com/symbol/adxs/short-interest#ixzz4Gtl9yq3a
Today NASDAQ releases its short interest report for stocks as of 7/31. The release time is after 4 PM ET -- after regular market close.
Correction! Short interest report for NASDAQ stocks as of 7/31, not 8/31.
Today NASDAQ releases its short interest report for stocks as of 8/31. The release time is after 4 PM ET -- after regular market close.
Today NASDAQ releases its short interest report for stocks as of 8/31. The release time is after 4 PM ET -- after regular market close.
With the Zika news I agree that investors will look for a solid Zika-related stock. Not a scam stock, for sure.
As a LT holder of GOVX I have been attracted by their approach and prospects but disappointed so far by the results.
Maybe the lack of our stock pps rise some expected is due to the competition. How fast can GOVX move to compete? For example:
Inovio Pharmaceuticals Doses First Subject in Zika Vaccine Clinical Trial
Phase I trial approved by US FDA and Health Canada
PLYMOUTH MEETING, Pa., July 26, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced the dosing of the first subject in its multi-center phase I trial to evaluate Inovio’s Zika DNA vaccine (GLS-5700). In addition to the previously announced US FDA approval for the conduct of the study, Health Canada’s Health Products and Food Branch has also approved this study, which will be conducted at clinical sites in Miami, Philadelphia, and Quebec City.
This phase I, open-label, dose-ranging study of 40 healthy adult volunteers is evaluating the safety, tolerability and immunogenicity of GLS-5700 administered with the CELLECTRA®-3P device, Inovio’s proprietary intradermal DNA delivery device. In preclinical testing, this synthetic vaccine induced robust antibody and T cell responses - the immune responses necessary to fight viral infections - in small and large animal models.
Thanks for the note on Barclays.
To correct the typo on trading volume, yesterday it was 6,418,753. Well over 11 million shares traded yesterday and today.
On 7/15 the short interest was a bit over 8 million shares, so the short interest ratio of 14.52 could be declining very fast. Will be interesting to see the SI on 8/1.
Terrible day, maybe more ahead in the month of August, for most bio stocks. Two examples I've been holding.
GOV# just got a huge government grant, but only a small amount immediately available, for innovative anti-virus vaccines. Up somewhat yesterday, but dropping again today. Shareholders disappointed . . . again.
OTOH the innovative immunology approach of ADX# has recently attracted collaborations by Astra Zeneca, Merck, and now today Amgen. The money and stock purchases by Amgen immediately sent the stock sharply higher. Longs are finally getting relief from the beat-down by shorts.
What will it take for AVXL longs to get control, and when will that occur? I don't know, but will hold the shares I recently purchased for favorable news. The shorts don't really gain until they cover. We still have plenty of economic and political uncertainty, as well as two more months of seasonal weakness for equities.
Can you substantiate that MVTG technology qualifies under the proviso quoted below (pg. 105 of the Official Call from Horizon 2020 Energy)?
"Projects shall include prototype testing under industrially relevant conditions. Any research that constitutes a technology
demonstration at large scale or a combination of CCS technologies proven at pre-demonstration pilot scale will not be considered for funding."
Also wonder where's R. J. Trotts, a former moderator?
Looking at charts and tech indicators, a 40 per cent rise off the May 12 low of $.50 may lead some traders to take short term profits.
The Barchart opinion indicators are at 100% Buy and some other technical figures show the price moving into various levels of resistance.
Of course LWLG prospects are getting better and better from recent PR's. Yet without third party verification the challenges of Polymer Photonics commercial development and integration "unknown unknowns" are still overshadowing clouds.
Bullish moves always seem to climb a "wall of worry." This tests the conviction of LT investors (especially those of us who are still in the red).
I agree with you. Of course the lithium story is strong and the fundamentals look great.
So Monday on the TSX and Tuesday on the OTC QX we will see if this tech indicator signaled a reverse. The barchart opinion indicators were also 100% Buy today. They signal a contrarian trader to sell.
That's why I sold late in the day on the 0.84 bid.
Thanks for the helpful answer. I scanned only one screenshot from the link which had 2015 at the bottom.
I just clicked a few more links: saw a few interesting pictures, but I don't read Chinese. Are any of the news articles in English?
Again LJ deserves our thanks. The 2015 date on the Web site concerns me. Any ideas on why? What does this imply?
Derivatives, like other financial instruments, have their legitimate and beneficial uses. All-to-frequently they are abused by some to the detriment of many.
The primary use of derivatives is not the formation of capital. It is risk management, which many businesses use an an integral part of their strategy, e.g., hedging of fuel costs by airlines, of grains by cereal producers, etc.
A Web search with the terms "derivatives risk management" shows strategies-tactics.com, New York Institute of Finance, The Wharton School (U. Penn), and Comptroller of the Currency as the top sites.
Like so many other areas, we would hope that the abuse of derivatives could be effectively curtailed. It's a complex subject.
In addition to the resource estimates mentioned by other posters here, I would expect newer technologies will result in greater energy density per unit of lithium. Recycling lithium batteries will also add capacity to producers of Li products IMO.